메뉴 건너뛰기




Volumn 46, Issue 4, 2006, Pages 624-629

Anticoagulation with low-molecular-weight heparin (dalteparin) in plasmapheresis therapy: Initial experience

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A INHIBITOR; DALTEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PROTHROMBIN; THROMBIN ANTITHROMBIN COMPLEX; TRANSACTIVATOR PROTEIN;

EID: 33645325148     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2006.00755.x     Document Type: Article
Times cited : (13)

References (29)
  • 1
    • 0036014092 scopus 로고    scopus 로고
    • Plasmapheresis: Technical aspects and indications
    • Madore F. Plasmapheresis: technical aspects and indications. Crit Care Clin 2002 18 375 92.
    • (2002) Crit Care Clin , vol.18 , pp. 375-92
    • Madore, F.1
  • 2
    • 0038779507 scopus 로고    scopus 로고
    • Plasmapheresis in immune haematology: Review of clinical outcome data with respect to evidence-based medicine and clinical experience
    • Baeyer H. Plasmapheresis in immune haematology: review of clinical outcome data with respect to evidence-based medicine and clinical experience. Ther Apher Dial 2003 7 127 40.
    • (2003) Ther Apher Dial , vol.7 , pp. 127-40
    • Baeyer, H.1
  • 3
    • 0038646302 scopus 로고    scopus 로고
    • Indications of plasma exchange for systemic vasculitis
    • Guillevin L Pagnoux C. Indications of plasma exchange for systemic vasculitis. Ther Apher Dial 2003 7 155 60.
    • (2003) Ther Apher Dial , vol.7 , pp. 155-60
    • Guillevin, L.1    Pagnoux, C.2
  • 4
    • 12344286801 scopus 로고    scopus 로고
    • Plasmapheresis in neurological diseases: Experience in 140 procedures in 47 patients
    • Nogates-Gaete J Valenzuela D Liendo F et al. Plasmapheresis in neurological diseases: experience in 140 procedures in 47 patients. Rev Med Chil 2004 123 295 8.
    • (2004) Rev Med Chil , vol.123 , pp. 295-8
    • Nogates-Gaete, J.1    Valenzuela, D.2    Liendo, F.3
  • 5
    • 0019314538 scopus 로고
    • Surface activation of blood coagulation, fibrinolysis and kinin formation
    • Heimark RL Kurachi RK Fujikawa K Davie EW. Surface activation of blood coagulation, fibrinolysis and kinin formation. Nature 1980 286 456 560.
    • (1980) Nature , vol.286 , pp. 456-560
    • Heimark, R.L.1    Kurachi, R.K.2    Fujikawa, K.3    Davie, E.W.4
  • 6
    • 0020445531 scopus 로고
    • Use of heparin for cytapheresis and plasmapheresis in a continuous flow centrifuge
    • Morales M Pizzuto J Reyna MA et al. Use of heparin for cytapheresis and plasmapheresis in a continuous flow centrifuge. Transfusion 1982 22 384 7.
    • (1982) Transfusion , vol.22 , pp. 384-7
    • Morales, M.1    Pizzuto, J.2    Reyna, M.A.3
  • 8
    • 0024315960 scopus 로고
    • Optimization of heparinization in clinical double filtration plasmapheresis
    • Hosokawa S Oyamaguchi A Yoshida O. Optimization of heparinization in clinical double filtration plasmapheresis. Int J Artif Organs 1989 12 544 8.
    • (1989) Int J Artif Organs , vol.12 , pp. 544-8
    • Hosokawa, S.1    Oyamaguchi, A.2    Yoshida, O.3
  • 9
    • 0024992853 scopus 로고
    • Clinical studies on adequate dosage of heparin during immunoadorption with membrane plasmapheresis
    • Hosokawa S Oyamaguchi A Yoshida O. Clinical studies on adequate dosage of heparin during immunoadorption with membrane plasmapheresis. J Clin Apheresis 1990 5 197 200.
    • (1990) J Clin Apheresis , vol.5 , pp. 197-200
    • Hosokawa, S.1    Oyamaguchi, A.2    Yoshida, O.3
  • 10
    • 0025010826 scopus 로고
    • Effect of anticoagulant on biocompatibility in membrane plasmapheresis
    • Omokawa S Malchesky PS Yamashita M et al. Effect of anticoagulant on biocompatibility in membrane plasmapheresis. Int J Artif Organs 1990 13 768 77.
    • (1990) Int J Artif Organs , vol.13 , pp. 768-77
    • Omokawa, S.1    Malchesky, P.S.2    Yamashita, M.3
  • 11
    • 0037560252 scopus 로고    scopus 로고
    • Influence of different heparin concentrations on the results of in vitro investigations in plasmaseperation technology using capillary membrane filters
    • Unger KU Haltern C Dohmen B Rossaint R. Influence of different heparin concentrations on the results of in vitro investigations in plasmaseperation technology using capillary membrane filters. Artif Organs 2003 27 649 57.
    • (2003) Artif Organs , vol.27 , pp. 649-57
    • Unger, K.U.1    Haltern, C.2    Dohmen, B.3    Rossaint, R.4
  • 12
    • 0034046318 scopus 로고    scopus 로고
    • The effect of plasmapheresis on the serum activity level of dalteparin: A case report
    • Sabloff M Wells PS. The effect of plasmapheresis on the serum activity level of dalteparin: a case report. Blood Coagul Fibrinolysis 2000 11 395 400.
    • (2000) Blood Coagul Fibrinolysis , vol.11 , pp. 395-400
    • Sabloff, M.1    Wells, P.S.2
  • 13
    • 0023828836 scopus 로고
    • Determination of human thrombin- antithrombin III-complex in plasma with an enzym-linked immunosorbent assay
    • Pelzer H Schwarz A Heimburger N. Determination of human thrombin- antithrombin III-complex in plasma with an enzym-linked immunosorbent assay. Thromb Haemost 1988 59 101 6.
    • (1988) Thromb Haemost , vol.59 , pp. 101-6
    • Pelzer, H.1    Schwarz, A.2    Heimburger, N.3
  • 14
    • 0026071629 scopus 로고
    • Determination of human prothrombin activation fragment 1+2 in plasma with an antibody against a synthetic peptide
    • Pelzer H Schwarz A Stüber W. Determination of human prothrombin activation fragment 1+2 in plasma with an antibody against a synthetic peptide. Thromb Haemost 1991 65 153 9.
    • (1991) Thromb Haemost , vol.65 , pp. 153-9
    • Pelzer, H.1    Schwarz, A.2    Stüber, W.3
  • 15
    • 0020085770 scopus 로고
    • Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/F1+2-fragment and thrombin-antithrombin-complex
    • Teiel JM Bauer KA Lau HK Rosenberg RD. Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/F1+2-fragment and thrombin-antithrombin-complex. Blood 1982 59 1086 97.
    • (1982) Blood , vol.59 , pp. 1086-97
    • Teiel, J.M.1    Bauer, K.A.2    Lau, H.K.3    Rosenberg, R.D.4
  • 16
    • 0026758761 scopus 로고
    • Multicentric evaluation of a new assay for prothrombin fragment 1+2 determination
    • Bruhn HD Conard J Manucci M et al. Multicentric evaluation of a new assay for prothrombin fragment 1+2 determination. Thromb Haemost 1992 68 413 7.
    • (1992) Thromb Haemost , vol.68 , pp. 413-7
    • Bruhn, H.D.1    Conard, J.2    Manucci, M.3
  • 17
    • 26444493740 scopus 로고
    • A simple chromogenic assay for heparin and heparin-linked anti-F Xa acitivity in plasma
    • Holmer E et al. A simple chromogenic assay for heparin and heparin-linked anti-F Xa acitivity in plasma. Thromb Haemost 1985 53 278 81.
    • (1985) Thromb Haemost , vol.53 , pp. 278-81
    • Holmer, E.1
  • 18
    • 0023787586 scopus 로고
    • An international standard for low molecular weight heparin
    • Barrowcliffe TW. An international standard for low molecular weight heparin. Thromb Haemost 1988 60 1 7.
    • (1988) Thromb Haemost , vol.60 , pp. 1-7
    • Barrowcliffe, T.W.1
  • 19
    • 7144260080 scopus 로고
    • Preliminary evaluation of repeated use of a low molecular weight heparin in hemodialysis for chronic renal failure
    • Anastassiades EG Lane DA Lynn A Curtis JR. Preliminary evaluation of repeated use of a low molecular weight heparin in hemodialysis for chronic renal failure. Proc Eur Dial Trans Assoc 1985 22 329 33.
    • (1985) Proc Eur Dial Trans Assoc , vol.22 , pp. 329-33
    • Anastassiades, E.G.1    Lane, D.A.2    Lynn, A.3    Curtis, J.R.4
  • 20
    • 0022857695 scopus 로고
    • Hemodialysis with low molecular weight heparin: Dosage requirement for the elimination of extracorporeal fibrin formation
    • Lane DA Ireland H Flynn A Anastassiades E Curtis JR. Hemodialysis with low molecular weight heparin: dosage requirement for the elimination of extracorporeal fibrin formation. Nephrol Dial Transplant 1986 1 179 35.
    • (1986) Nephrol Dial Transplant , vol.1 , pp. 179-35
    • Lane, D.A.1    Ireland, H.2    Flynn, A.3    Anastassiades, E.4    Curtis, J.R.5
  • 21
    • 0023114607 scopus 로고
    • A single dose of a low molecular weight heparin fragment for anticoagulation during hemodialysis
    • Ljunberg B Blombäck M Johnsson H Lins LE. A single dose of a low molecular weight heparin fragment for anticoagulation during hemodialysis. Clin Nephrol 1987 27 31 5.
    • (1987) Clin Nephrol , vol.27 , pp. 31-5
    • Ljunberg, B.1    Blombäck, M.2    Johnsson, H.3    Lins, L.E.4
  • 22
    • 0025971904 scopus 로고
    • Acute dialysis: PMN-elastase as a new parameter for controlling individual anticoagulation with low molecular weight heparin (Fragmin®)
    • Swars H Hafner G Weilemann LS et al. Acute dialysis: PMN-elastase as a new parameter for controlling individual anticoagulation with low molecular weight heparin (Fragmin®). Intens Care Med 1991 17 52 6.
    • (1991) Intens Care Med , vol.17 , pp. 52-6
    • Swars, H.1    Hafner, G.2    Weilemann, L.S.3
  • 23
    • 0025203322 scopus 로고
    • Clinical application of Fragmin (FR-860) in hemodialysis: Multicenter cooperative study in Japan
    • Suzuki T Ota K Naganuma S et al. Clinical application of Fragmin (FR-860) in hemodialysis: multicenter cooperative study in Japan. Semin Thromb Hemost 1990 16 46 54.
    • (1990) Semin Thromb Hemost , vol.16 , pp. 46-54
    • Suzuki, T.1    Ota, K.2    Naganuma, S.3
  • 24
    • 0032794346 scopus 로고    scopus 로고
    • A single dose of dalteparin effectively prevent clotting during haemodialysis: Anticoagulation intensity sufficient for haemodialysis does not prevent activation of coagulation and platelets
    • Sagedal S Hartmann A Sundstrom K et al. A single dose of dalteparin effectively prevent clotting during haemodialysis: anticoagulation intensity sufficient for haemodialysis does not prevent activation of coagulation and platelets. Nephrol Dial Transplant 1999 14 1943 7.
    • (1999) Nephrol Dial Transplant , vol.14 , pp. 1943-7
    • Sagedal, S.1    Hartmann, A.2    Sundstrom, K.3
  • 25
    • 0035025371 scopus 로고    scopus 로고
    • Anticoagulation intensity sufficient for haemodialysis does not prevent activation of coagulation and platelets
    • Sagedal S Hartmann A Sundstrom K Bjornsen S Brosstad F. Anticoagulation intensity sufficient for haemodialysis does not prevent activation of coagulation and platelets. Nephrol Dial Transplant 2001 16 987 93.
    • (2001) Nephrol Dial Transplant , vol.16 , pp. 987-93
    • Sagedal, S.1    Hartmann, A.2    Sundstrom, K.3    Bjornsen, S.4    Brosstad, F.5
  • 27
    • 0031680310 scopus 로고    scopus 로고
    • College of American Pathologists Conference XXXI on Laboratory Monitorin of Anticoagulant Therapy: The clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban
    • Laptosa M Green K Elizabeth MV et al. College of American Pathologists Conference XXXI on Laboratory Monitorin of Anticoagulant Therapy: the clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban. Arch Pathol Lab Med 1998 122 799 807.
    • (1998) Arch Pathol Lab Med , vol.122 , pp. 799-807
    • Laptosa, M.1    Green, K.2    Elizabeth, M.V.3
  • 28
    • 3242734130 scopus 로고    scopus 로고
    • Is laboratory monitoring of low-molecular-weight heaprin therapy necessary? Yes
    • Harenberg J. Is laboratory monitoring of low-molecular-weight heaprin therapy necessary? Yes. J Thromb Haemost 2004 2 547 50.
    • (2004) J Thromb Haemost , vol.2 , pp. 547-50
    • Harenberg, J.1
  • 29
    • 0025996472 scopus 로고
    • Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin
    • Nieuwenhuis HK Albada J Banga JD et al. Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin. Blood 1991 78 2337 43.
    • (1991) Blood , vol.78 , pp. 2337-43
    • Nieuwenhuis, H.K.1    Albada, J.2    Banga, J.D.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.